Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2012Biology of Blood and Marrow TransplantationOpen Access

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJason LawGuy's and St Thomas' NHS Foundation TrustMCMorton J. CowanBlood Systems Research InstituteCDChristopher C. DvorakCity College of San Francisco

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Law et al. (2012) studied this question.

synapsesocial.com/papers/6a827d69d8fdafe7792a4de4https://doi.org/10.1016/j.bbmt.2012.05.006
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting of Natural Killer Cells by Rabbit Antithymocyte Globulin and Campath-1H: Similar Effects Independent of Specificity2009 · 42 citations
  2. 2Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation2010 · 273 citations
  3. 3Hematopoietic Stem Cell Transplantation for Bone Marrow Failure Syndromes in Children2009 · 88 citations
  4. 4Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications2003 · 193 citations
  5. 5Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation2003 · 132 citations